ARVINAS INC
NASDAQ: ARVN (Arvinas, Inc.)
Last update: yesterday, 10:35PM7.39
-0.18 (-2.38%)
| Previous Close | 7.57 |
| Open | 7.40 |
| Volume | 1,095,315 |
| Avg. Volume (3M) | 2,701,836 |
| Market Cap | 539,406,464 |
| Price / Sales | 1.25 |
| Price / Book | 0.820 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -10.92% |
| Operating Margin (TTM) | 37.82% |
| Diluted EPS (TTM) | -0.660 |
| Quarterly Revenue Growth (YOY) | 646.20% |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 4.58 |
| Operating Cash Flow (TTM) | -250.70 M |
| Levered Free Cash Flow (TTM) | -2.69 M |
| Return on Assets (TTM) | -5.39% |
| Return on Equity (TTM) | -7.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Arvinas, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.75% |
| % Held by Institutions | 86.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 31 Mar 2025 | 1,585,721 |
| Nextech Invest, Ltd. | 31 Mar 2025 | 1,408,394 |
| Nextech Invest Ltd. | 31 Dec 2024 | 1,408,394 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (HC Wainwright & Co., 224.76%) | Buy |
| Median | 11.00 (48.85%) | |
| Low | 8.00 (Goldman Sachs, 8.25%) | Hold |
| Average | 13.73 (85.79%) | |
| Total | 7 Buy, 6 Hold | |
| Avg. Price @ Call | 7.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 02 Jun 2025 | 9.00 (21.79%) | Hold | 7.33 |
| UBS | 15 May 2025 | 21.00 (184.17%) | Buy | 6.26 |
| Morgan Stanley | 09 May 2025 | 11.00 (48.85%) | Hold | 6.61 |
| BMO Capital | 05 May 2025 | 10.00 (35.32%) | Buy | 7.63 |
| Citigroup | 05 May 2025 | 9.50 (28.55%) | Hold | 7.63 |
| Truist Securities | 05 May 2025 | 11.00 (48.85%) | Hold | 7.63 |
| 09 Apr 2025 | 21.00 (184.17%) | Buy | 6.73 | |
| Barclays | 02 May 2025 | 16.00 (116.51%) | Buy | 7.72 |
| Goldman Sachs | 02 May 2025 | 8.00 (8.25%) | Hold | 7.72 |
| 17 Apr 2025 | 12.00 (62.38%) | Hold | 8.60 | |
| Guggenheim | 02 May 2025 | 16.00 (116.51%) | Buy | 7.72 |
| HC Wainwright & Co. | 02 May 2025 | 24.00 (224.76%) | Buy | 7.72 |
| 07 Apr 2025 | 81.00 (996.08%) | Buy | 6.37 | |
| Jefferies | 02 May 2025 | 10.00 (35.32%) | Hold | 7.72 |
| Piper Sandler | 02 May 2025 | 14.00 (89.45%) | Buy | 7.72 |
| Wells Fargo | 02 May 2025 | 19.00 (157.10%) | Buy | 7.72 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |